Pfizer launches “An agreement for


Pfizer will supply all of its drugs and vaccines protected by current and future patents available in the US or EU on a not-for-profit basis to 45 low-income countries.

Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to commit to joining the Agreement. Health officials in these countries will help identify and address barriers beyond supply to inform rollout in all 45 low-income countries.

Pfizer is calling on global health leaders and organizations to join the Accord, contributing their expertise and resources to close the health equity gap and help create a healthier world for 1.2 billion people. people.

DAVOS, Switzerland, May 25, 2022 /PRNewswire/ — Pfizer Inc. (NYSE: PFE) today launched “A Deal for a Healthier World.” This groundbreaking initiative aims to provide all of Pfizer’s high-quality, patented medicines and vaccines available in the United States or European Union on a not-for-profit basis to 1.2 billion people in 45 low-income countries. The Agreement aims to significantly reduce the health inequalities that exist between many low-income countries and the rest of the world.

“As we learned during the global rollout of the COVID-19 vaccine, supply is only the first step in helping patients. We will work closely with global health leaders to drive improvements in diagnostics, education, infrastructure, storage and more are overcome, can we end healthcare inequities and deliver to all patients,” said Pfizer Chairman and CEO Albert Bourla.

Accord countries include the 27 low-income countries as well as 18 lower-middle-income countries that have moved from low-income to lower-middle-income classification over the past ten years. Pfizer will work with health officials in Rwanda, Ghana, Malawi, Senegal and Uganda identify early insights and opportunities to ensure that all medicines and vaccines can reach those who need them. This will include expertise to support diagnosis, education and training of healthcare professionals as well as supply chain management and other infrastructure improvements. Lessons learned from these five countries will be applied to support deployment in the remaining forty countries.

Pfizer will also work with Agreement Participants to identify fast and efficient regulatory pathways and procurement processes to reduce the time it takes to make new medicines and vaccines available in these countries.

Under the Agreement, Pfizer has committed to supply 23 drugs and vaccines that treat infectious diseases, certain cancers, and rare and inflammatory diseases. Making these drugs and vaccines more readily available has the potential to address non-communicable and infectious diseases that claim the lives of nearly one million people every year in these countries and chronic diseases that have a significant impact on quality of life. at least half a million more people.[1]. As Pfizer introduces new drugs and vaccines, these products will also be included in the Accord portfolio on a not-for-profit basis.

The Agreement also aims to establish faster access to Pfizer’s future medicines and vaccines on a not-for-profit basis for all 45 countries, especially those dealing with diseases that have a disproportionate impact on global health. To continue this commitment, Pfizer, with funding from the Bill & Melinda Gates Foundation, is advancing work on the development of candidate vaccines for the prevention of group B streptococcus (GBS), which is a leading cause of stillbirth and death. neonatal in low-income countries. They are also discussing the possibilities of supporting the development of a vaccine against respiratory syncytial virus (RSV), another maternal vaccine.

“Everyone, wherever they live, should have the same access to innovative, life-saving medicines and vaccines,” said

Bill Gates , co-chair of the Bill & Melinda Gates Foundation. “The Accord for a Healthier World could help millions more people in low-income countries get the tools they need to lead healthy lives. Pfizer is setting an example for other companies.”

“Fast and affordable access to the most advanced medicines and vaccines is the cornerstone of global health equity. Pfizer’s commitment to the Accord program sets a new standard in this regard. Combined with additional investments in strengthening africa public health systems and pharmaceutical regulators, the Agreement is an important step towards sustainable health security for countries at all income levels,” said His Excellency Paul Kagame, President of Rwanda.

“We must continue to strive to provide quality health care so that everyone can live longer, stronger and healthier lives,” said His Excellency the President. Nana Addo Dankwa Akufo-AddoPresident of Ghana. “This will require close cooperation between the public and private sectors. We are proud to join this Accord to work together on this important goal.”

Senegal proudly supports the launch of A Deal for a Healthier World to improve equity and health outcomes for people in our country and around the world,” said His Excellency Macky Sall, President of Senegal. “Together we will work for a better world.”

“What’s great about this agreement is that it helps low-income countries without undermining their dignity and agency as people, because it’s a real partnership that involves both Pfizer and countries like Malawi sharing the burden of costs and tasks in the production and delivery of supplies that will save millions of lives. This is the way to tackle all global issues,” said His Excellency Lazarus Chakwera, President of Malawi.

“It is time to close the health equity gap,” said His Excellency Yoweri Museveni, President of Uganda. “Uganda is proud to join the Accord, and we are committed to working with Pfizer and all Accord partners to find new ways to address access challenges. »

Further details on An Accord for a Healthier World are available at

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring people therapies that dramatically extend and improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of healthcare products, including innovative medicines and vaccines. Every day, Pfizer colleagues work in developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. In line with our responsibility as one of the world’s leading innovative biopharmaceutical companies, we work with healthcare providers, governments and local communities to support and expand access to reliable and affordable healthcare in the whole world. For over 170 years, we’ve worked to make a difference for everyone who counts on us. We regularly post information that may be important to investors on our website at Also, to learn more, visit us at and follow us on Twitter at @Pfizer and @PfizerNewsLinkedIn, YouTube and like us on Facebook at

Notice of Disclosure
The information contained in this press release is as of May 25, 2022. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking statements regarding the company’s launch of “A Deal for a Healthier World”, its efforts to provide all of its medicines and vaccines protected by current and future patents available in the US or EU on a profit basis to 45 low-income countries and its collaborations with global health leaders, which involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, the start and/or completion dates of our clinical trials, the dates regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of new adverse clinical data and further analyzes of existing clinical data; ; decisions of regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that may affect the availability or commercial potential of Pfizer’s product candidates, including product development or therapies by other companies; manufacturing capacities or abilities; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of such recommendations; uncertainties inherent in business and financial planning, including, without limitation, risks relating to Pfizer’s business and prospects, adverse developments in Pfizer’s markets or adverse developments in U.S. or global capital markets, credit markets, the regulatory environment or economies in general; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A more detailed description of risks and uncertainties is available in Pfizer’s Annual Report on Form 10-K for the year ended. December 31, 2021 and in its subsequent reports on Form 10-Q, including the sections titled “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K , all of which are filed with the United States Securities and Exchange Commission and available at and

Pfizer contact details:
Media Relations
+1 (212) 733-1226
[email protected]

Investor Relations
+1 (212) 733-4848
[email protected]

[1] Internal calculations based on data collected via

[2] Eligibility (

View original content: – people-living-in-45-low-income-countries-301554774.html



Comments are closed.